2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. PCSK9

PCSK9

Proprotein convertase subtilisin/kexin type 9

 

PCSK9 Related Products (65):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112598A
    PF-06815345 hydrochloride
    		Inhibitor 98.15%
    PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse.
    PF-06815345 hydrochloride
  • HY-130245
    PCSK9 degrader 1
    		Degrader 98.26%
    PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a Ki of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor.
    PCSK9 degrader 1
  • HY-W510159
    5-O-Methylembelin
    		Inhibitor 98.84%
    5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, inducible degrader of the low-density lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2) mRNA expression.
    5-O-Methylembelin
  • HY-148687
    SPC5001
    		Inhibitor
    SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′.
    SPC5001
  • HY-143220
    SS(no Galnac)-Inclisiran sodium
    		Inhibitor
    SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    SS(no Galnac)-Inclisiran sodium
  • HY-P2276A
    Pep2-8 TFA
    		Inhibitor 99.44%
    Pep2-8 is a peptide which has enhanced the antagonistic activity of proprotein convertase subtilin/ kexin 9 type (PCSK9).
    Pep2-8 TFA
  • HY-148758
    PCSK9-IN-13
    		Inhibitor 98.00%
    PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM.
    PCSK9-IN-13
  • HY-112598
    PF-06815345
    		Inhibitor
    PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse.
    PF-06815345
  • HY-143223
    AS(3n-2)-Inclisiran
    		Inhibitor
    AS(3n-2)-Inclisiran is the antisense of Inclisiran with 3 N random site after the 2 bp spacer. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    AS(3n-2)-Inclisiran
  • HY-139998
    PCSK9-IN-3
    		Inhibitor
    PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitor.
    PCSK9-IN-3
  • HY-120088
    PF-06446846
    		Inhibitor
    PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.
    PF-06446846
  • HY-P99871
    Ebronucimab
    		Inhibitor
    Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells.
    Ebronucimab
  • HY-P99626
    Frovocimab
    		Inhibitor
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.
    Frovocimab
  • HY-P99773
    Ongericimab
    		Inhibitor
    Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia.
    Ongericimab
  • HY-P99696
    Lerodalcibep
    Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases.
    Lerodalcibep
  • HY-P99822
    Recaticimab
    		Inhibitor 99.71%
    Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia.
    Recaticimab
  • HY-P99816
    Ralpancizumab
    		Inhibitor
    Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke.
    Ralpancizumab
  • HY-147252
    Bezeparsen
    		Inhibitor
    Bezeparsen is a PCSK9 synthesis inhibitor.
    Bezeparsen
  • HY-128334
    PCSK9 modulator-2
    		Modulator
    PCSK9 modulator-2 (Compound 1) is a potent modulator of PCSK9 with an EC50 value of 202 nM. PCSK9 is a recently validated target for lowering low-density lipoprotein cholesterol (LDL-C). PCSK9 modulator-2 has the potential for the research of hyperlipidemia.
    PCSK9 modulator-2
  • HY-153452
    PCSK9-IN-16
    		Inhibitor
    PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research.
    PCSK9-IN-16